Mosaic Financial Group LLC Has $1.47 Million Stock Holdings in Novartis AG (NYSE:NVS)

Mosaic Financial Group LLC increased its position in Novartis AG (NYSE:NVS) by 4.1% during the fourth quarter, Holdings Channel reports. The firm owned 15,079 shares of the company’s stock after buying an additional 588 shares during the quarter. Novartis makes up approximately 1.1% of Mosaic Financial Group LLC’s portfolio, making the stock its 24th largest holding. Mosaic Financial Group LLC’s holdings in Novartis were worth $1,467,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVS. Bryn Mawr Capital Management LLC lifted its position in shares of Novartis by 0.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company’s stock valued at $1,254,000 after buying an additional 100 shares during the last quarter. Rothschild Investment LLC lifted its holdings in Novartis by 0.6% during the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock valued at $1,623,000 after purchasing an additional 101 shares during the last quarter. Meridian Wealth Management LLC boosted its position in Novartis by 2.6% during the fourth quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company’s stock worth $405,000 after purchasing an additional 106 shares during the period. Angeles Wealth Management LLC increased its holdings in shares of Novartis by 3.5% in the fourth quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company’s stock valued at $316,000 after purchasing an additional 110 shares during the last quarter. Finally, Heritage Family Offices LLP raised its position in shares of Novartis by 1.9% in the fourth quarter. Heritage Family Offices LLP now owns 6,107 shares of the company’s stock valued at $594,000 after purchasing an additional 112 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 1.0 %

Shares of NYSE:NVS opened at $111.48 on Tuesday. The business’s 50 day simple moving average is $108.20 and its 200 day simple moving average is $107.10. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The company has a market capitalization of $227.87 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.70 and a beta of 0.53.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, research analysts anticipate that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Announces Dividend

The company also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were given a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis’s payout ratio is presently 42.69%.

Wall Street Analysts Forecast Growth

NVS has been the subject of several research analyst reports. Barclays reaffirmed an “underweight” rating on shares of Novartis in a report on Monday, February 3rd. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. UBS Group reiterated a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Finally, HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.